PCP
MYGN icon

Proficio Capital Partners’s Myriad Genetics MYGN Stock Holding History

Proficio Capital Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-138
Closed -$4K – 1017
2019
Q2 		$4K Buy
+138
New +$3.9K ﹤0.01% 1302

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Proficio Capital Partners's MYGN Position: Q3 2019 in Review

Proficio Capital Partners sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 138 shares — an estimated $4K sold.

Proficio Capital Partners first reported a position in MYGN in Q2 2019 and held it in 1 quarter. The position peaked at $4K in Q2 2019. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

  • Proficio Capital Partners reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 138 Myriad Genetics shares in Q3 2019, an estimated $4K.
  • Proficio Capital Partners first reported a position in Myriad Genetics in Q2 2019 and held it in 1 quarter.
  • Proficio Capital Partners's Myriad Genetics position peaked at $4K in Q2 2019.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.